… on prognosis, beta-blocker therapy is now indicated in all the patients with chronic … of patients
on beta-blocker therapy who develop decompensated HF and who need inotropic therapy …

… lists from reviews of β-blocker therapy identified further trials. To be included in this meta-analysis,
β-blocker therapy had to be given for at least 3 months. In patients who were in NYHA …

… of overcompensating neurohormonal activation in chronic heart failure. However, clinical
doubts … in β-blocker therapy of advanced congestive heart failure, 15 consecutive patients were …

… the betablocker treatment. A further report of patients with idiopathic dilated cardiomyopathy
indicated improvement in hemodynamic status and symptoms with beta-blockade (68) and …

… However, there is a paucity of data about effective treatment for this condition. … of beta blocker
therapy for 3 months before admission on the two-year survival of patients with heart failure …

… emerged at follow-up for 3 years but not for 1 year in patients with HFpEF [32]. … -blocker
therapy may be key determinants of the effects of β-blockers on clinical events in HFpEF patients. …

… heart failure 5–9. In order to evaluate the amplitude and heterogeneity of the beta-blocker
effect in heart failure… controlled trials testing oral beta-blocker treatment compared to placebo, (…

… Case–control studies suggest, however, that β-blockers may reduce myocardial infarction
in patients with hypertension (43, 44). We observed that calcium-channel blocker therapy was …

… benefit for beta-blocker therapy in patients with heart failure. In … of spironolactone in patients
with severe heart failure. Other … to stay abreast of developments in heart failure treatment. …

… Our findings are consistent with a meta-analysis of the effect of β-blocker therapy in heart
failure, which found that the addition of β-blocker therapy to conventional treatment was …